海南自贸港药品、医疗器械"零关税"政策明确，在博鳌乐城国际医疗旅游先行区内注册登记具有独立法 人资格并经认定的医疗机构、医学教育高等院校、医疗类科研院所，进口政策规定范围内的药品、医疗 器械，可享受免征进口关税、进口环节增值税和消费税。此举可降低医疗机构运营成本，为患者就医减 轻负担。 "这项政策对于我们这些在乐城内注册的医疗机构来说可谓是'锦上添花'，不仅可以减轻患者用药用械 成本，也为我们企业资金周转提供了很大的便利。"海南博鳌超级医院相关负责人冯家龙说。 （来源：工人日报） 为保障"零关税"药械政策实施，海口海关积极研究优化通关流程，深入走访调研了解不同类型企业享惠 政策堵点痛点，研提解决措施，让政策红利精准触及享惠主体。 本报讯（记者赖书闻 通讯员刘一鸣）自2024年12月31日首票业务落地以来，海南自贸港药品、医疗器 械"零关税"政策已平稳运行一周年，政策红利持续释放。据海口海关统计，截至2025年12月31日，海南 累计进口"零关税"药械货值约4.6亿元，减免税款约6200万元。 下一步，海口海关将继续优化监管服务，引导企业用好用足政策，进一步推动"零关税"药械政策红利释 放，助力乐城先行区打造全 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603127 证券简称：昭衍新药 公告编号：2026-001 北京昭衍新药研究中心股份有限公司 关于员工持股计划回购股份注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 回购注销原因：北京昭衍新药研究中心股份有限公司（以下简称"公司"）已终止实施2021年及2022年 A股员工持股计划，公司拟注销回购专用账户中的A股共计129,114股。 ● 本次注销股份的有相关情况： ■ 一、本次员工持股计划回购股份注销已履行的决策程序和信息披露情况 （一）2021年A股员工持股计划 公司于2021年9月21日召开第三届董事会第二十九次会议和第三届监事会第二十次会议、于2022年1月19 日召开2022年第一次临时股东大会审议并通过了《关于公司〈2021年A股员工持股计划（草案）及其摘 要的议案》、《关于公司〈2021年A 股员工持股计划管理办法〉的议案》、《关于提请股东大会授权董 事会全权办理员工持股计划相关事宜的议案》，公司实施2021年A ...

Core Viewpoint - The launch of the public hospital reform and high-quality development demonstration project in Xicheng District, Beijing aims to enhance healthcare services through the integration of artificial intelligence and digital technologies in medical practices [1][2] Group 1: Project Overview - The demonstration project will be implemented over three years, focusing on collaborative governance in healthcare, hierarchical diagnosis and treatment, comprehensive reform of public hospitals, and the empowerment of digital technology [1] - The project aims to create replicable and promotable "Xicheng experience" to improve regional healthcare service levels [1] Group 2: Key Tasks and Measures - The implementation plan includes four major tasks and 13 reform measures, emphasizing the sharing of medical resources and the establishment of four centers: medical imaging, testing, pathology, and telemedicine [1] - A "one bed for the entire district" sharing mechanism will be explored, along with pilot programs for unified procurement of drugs, consumables, and equipment to achieve cost reduction and efficiency [1] Group 3: Hospital Development - The project will clarify the functional positioning of district hospitals through "one hospital, one policy" and promote key renovation projects like the revitalization of hospitals and standardized construction of community health service centers [1] - There will be a focus on strengthening specialties in traditional Chinese medicine, rehabilitation, and addressing shortages in geriatrics, pediatrics, psychiatry, and infectious diseases [1] Group 4: Digital Integration - The initiative will deepen the integration of digital technologies, establishing a unified platform for district hospitals, community health, public health, and health information to eliminate information barriers [2] - The project will provide smart health monitoring devices for the elderly and key chronic disease populations, facilitating proactive and continuous health management [2]

高频业务便捷办：支持"异地备案""信息查询"等高频医保业务线上办理，有效分流窗口压力，打破时间 与空间限制，非工作时段也能保障群众顺畅办事，让医保服务更高效省心。 场景延伸多元化：深度融合医院服务场景，未来将拓展"诊间结算""异地结算报错协同""住院查房辅 助""就诊指南查询""专家信息介绍"等多元功能，从医保服务延伸至全流程就医场景，打造一站式智能 服务生态。 作为具备多模态交互能力的人工智能体，"小金灵"能主动精准感知用户意图、理解复杂语义。未来将深 度融合医院"服务知识库"，延伸"诊间结算""异地结算报错协同""住院查房辅助""门诊就诊指南""住院服 务指南""内线电话查询""专家信息介绍"等多元化功能，将服务从医保领域全面拓展至全流程就医场 景，为患者提供一站式、人性化的智能服务，让就医之路更顺畅。 数字化转型浪潮下，人工智能已成为优化医疗服务、破解就医痛点的核心引擎， 近日，江苏省人民医 院（南京医科大学第一附属医院、江苏省妇幼保健院）携手南京医保引入智能服务载体"小金灵"正式入 驻医院。 该院院长刘云表示，"小金灵"入驻是医院智慧医疗服务建设的关键突破，也是AI技术赋能医保服务的重 要实践。医院始 ...

Market Overview - On January 6, the three major indices collectively rose, with the Shanghai Composite Index reaching a ten-year high, closing up 1.5% [1] - The total trading volume in A-shares reached 2.83 trillion yuan, an increase of 265 billion yuan compared to the previous trading day [1] - Over 4,100 stocks in the market rose, with 143 stocks hitting the daily limit, marking the second consecutive day of over a hundred stocks reaching the limit [1] - The commercial aerospace and brain-computer interface concepts continued to show strong performance [1] Company Announcements - China Satellite announced that its stock price has risen 156.07% since December 3, 2025, significantly outpacing the 23.92% increase in the military industry and 5.31% in the Shanghai Composite Index, indicating a potential overvaluation [3] - China Satellite warned of high trading risks due to market sentiment and irrational speculation, stating that its stock price is detached from its fundamentals [3] - China Satcom also indicated that its stock price has significantly deviated from its fundamentals, with a notable "hot potato" effect in trading, suggesting a high risk of a price drop [4] - Beidou Star Communication noted that its stock price has deviated by over 20% in the last three trading days, highlighting the high market interest in commercial aerospace concepts, while its main business includes satellite navigation products [5] - LeiKe Defense reported a 58.10% increase in stock price over five consecutive trading days, with no significant changes in fundamentals, indicating potential market overheating [6] - Aerospace Electronics announced a 123.23% increase in stock price since November 27, 2025, significantly higher than industry and index increases, warning of trading risks [7] - Aerospace Universe stated that its stock price has risen significantly, with a projected commercial aerospace revenue contribution of less than 15% for 2025 [8] - Aerospace Changfeng clarified that it does not engage in brain-computer interface or commercial aerospace businesses, despite being categorized as such [10] - Sanbo Brain Science indicated that it does not involve in the research or sales of brain-computer interface products, with minimal impact on its overall revenue [13] - Xiangyu Medical is focusing on non-invasive brain-computer interface technology, with no significant sales achieved yet [14] - Mylande announced that its brain-computer interface products are still in the research and development phase, with no major impact on its financial performance [15] - Fenglong Co. reported a 94.92% increase in stock price over seven consecutive trading days, warning of high speculation risks and potential trading halts if prices continue to rise [20][23]

Group 1 - Xinfeng Pharmaceutical is facing criminal charges for unit bribery, which may negatively impact its profits [2] - Aerospace Electronics has seen a stock price increase of 123.23% since November 27, 2025, significantly outpacing the industry and market, indicating potential irrational market behavior [3] - Chipone Technology has completed the acquisition of Zhudian Semiconductor, gaining a 40% stake and control over the company [4] Group 2 - Chaoying Electronics has increased its investment in AI high-end printed circuit board expansion from 1.468 billion to 3.315 billion yuan, with a production capacity target of 166,500 square meters annually [5] - Yihuilong's Brain Machine Star Chain is developing non-invasive brain-machine interface products, but they are still in early stages and not yet registered [6] - Aerospace Changfeng has confirmed it is not engaged in brain-machine interface or commercial aerospace businesses, despite being categorized as such [7] Group 3 - Guosheng Technology's stock will be suspended for trading on January 7, 2026, due to significant price fluctuations, with a cumulative increase of 370.20% since October 31, 2025 [9] - Xiangyu Medical focuses on non-invasive brain-machine interface technology, with no large-scale sales achieved yet, but aims to cover over 1,000 top-tier hospitals by 2026 [10] - Jiamai Packaging's stock has risen by 230.48% from December 17, 2025, leading to a trading suspension for review [11] Group 4 - Zhongtai Co. expects a net profit of 420 million to 480 million yuan for 2025, recovering from a loss of 77.96 million yuan in the previous year [19] - Lier Chemical anticipates a net profit increase of 113.62% to 132.19% for 2025, driven by rising product demand [20] - Pengding Holdings reported a 30.74% increase in consolidated revenue for December 2025, totaling 424.355 million yuan [21] Group 5 - Times New Materials signed a sales contract for wind turbine blades worth approximately 3.32 billion yuan [31] - Jinggong Steel Structure won a bid for a project worth 824 million yuan, representing 4.46% of its latest audited revenue [32] - Robotech's subsidiary ficonTEC signed a significant contract worth approximately 7.7 million euros for automated optical switch packaging [33]

Core Viewpoint - The article discusses the ongoing expansion of hospital bed capacity in China, highlighting the need for reform in public hospitals to address issues such as high inpatient rates and the siphoning effect of higher-tier hospitals on patients from lower-tier facilities [3][4]. Group 1: Hospital Bed Capacity and Utilization - China's hospital bed capacity has been increasing, with the number of beds per thousand people surpassing 7, significantly higher than in developed countries [3]. - The bed utilization rates for primary, secondary, and tertiary hospitals have shown a year-on-year decline, indicating a shift in demand and utilization patterns [4]. Group 2: Policy and Reform Initiatives - The National Health Commission has outlined a strategy for 2026 focusing on "strengthening the foundation, stabilizing secondary hospitals, and controlling tertiary hospitals," aiming to optimize the structure and function of medical institutions [3]. - The 2024 health development report indicates a slowdown in the expansion of public hospital beds, with the number expected to rise from 7.23 beds per thousand people in 2023 to 7.32 in 2024 [4]. Group 3: Regional Challenges and Adjustments - Many county-level hospitals are experiencing patient outflow and vacant beds, exacerbated by the siphoning effect from urban hospitals, leading to financial losses in county healthcare systems [4]. - Provinces like Shanghai, Jiangsu, and Henan are adjusting their plans for tertiary hospital setups, limiting the number of branches to three, in response to declining purchasing power for social medical services [4].

Core Viewpoint - TPG is nearing a deal to acquire Optum UK's business from UnitedHealth, with the transaction valued between £1.2 billion and £1.4 billion, and an announcement may come in the next few weeks, although the deal is not finalized and could still fall through [1] Group 1 - The acquisition price for Optum UK is reported to be between £1.2 billion and £1.4 billion [1] - TPG may seek to merge Optum UK with Nextech, a US-based electronic medical records software provider [1] - The deal is expected to be announced in the coming weeks, but it remains subject to finalization [1]

今日焦点 20CM两连板三博脑科：目前不涉及脑机接口产品的研发、生产及销售 三博脑科公告称，公司股票于2026年1月5日、1月6日连续两个交易日内收盘价格涨幅偏离值累计超过 30%，属于股票交易异常波动情形。公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提 供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调 控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响，敬请注意投资风险。 2连板翔宇医疗：截至2025年末脑机接口相关产品尚未实现规模化销售 翔宇医疗发布异动公告，近期资本市场对人脑工程、脑机接口等概念关注度较高，相关板块股价涨幅较 大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、认知言语、吞咽等康复全场 景布局，与当前国际上的侵入式脑机接口技术路线存在差异。公司在脑机接口方面的投入，目前在技 术、产品、渠道市场等方面形成一定的布局，但招投标和销售等具有滞后性，截至2025年末，相关产品 尚未实现规模化销售，营收占比较小。 6天4板中国卫通：目前股价已处于历史最高点，已严重脱离基本面存在短期大幅下跌的风险 中国卫通发布股票交易风 ...

【导读】多只牛股公告 兄弟姐妹们啊，今晚多只商业航天、脑机接口概念的牛股齐发公告，不是停牌核查就是提示风险！ 6天4板北斗星通：商业航天仅为公司产品和服务的应用场景之一 中国卫星（600118）公告，公司股票自2025年12月3日以来收盘价格累计上涨幅度为156.07%，同期申 万军工行业涨幅23.92%，上证A指涨幅5.31%，公司股票短期涨幅明显高于同期行业及上证指数涨幅， 但公司基本面未发生重大变化，存在市场情绪过热、非理性炒作风险，公司股票击鼓传花效应明显，交 易风险极大，存在股价短期快速回落风险。 北斗星通（002151）公告称，公司股票交易价格连续3个交易日收盘价格涨幅偏离值累计超过20%，属 于股票交易异常波动情形。公司留意到近期市场对于商业航天概念股的关注度颇高，公司主营业务为卫 星导航芯片、模组、天线、数据服务，下游应用场景包括测量测绘、智能驾驶、智慧农业、割草机器 人、无人机等，商业航天仅为公司产品和服务的应用场景之一，请投资者注意风险。 航天环宇：预计2025年公司商业航天相关收入占比不足15% 航天环宇公告，公司股票于2025年12月31日、2026年1月5日、1月6日连续三个交易日内 ...